ZURA BIO LIMITED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.69 USD | +1.08% |
|
+8.67% | -0.64% |
| May. 06 | Zura Bio Limited announced that it has received $112.4935 million in funding from a group of investors | CI |
| May. 03 | Piper Sandler Starts Zura Bio With Overweight Rating, $26 Price Target | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 289M |
|---|---|---|---|---|---|
| Net income 2024 * | -48M | Net income 2025 * | -62M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-5.03
x | P/E ratio 2025 * |
-4.51
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.06% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -1.07% | ||
| 1 week | +8.67% | ||
| Current month | +8.67% | ||
| 1 month | +69.96% | ||
| 3 months | +16.00% | ||
| 6 months | +4.27% | ||
| Current year | -0.64% |
1 week
4.12
4.84
1 month
2.664.95
Current year
2.004.95
1 year
2.0014.00
3 years
2.0037.55
5 years
2.0037.55
10 years
2.0037.55
| Managers | Title | Age | Since |
|---|---|---|---|
Someit Sidhu
FOU | Founder | 34 | 22-01-17 |
Robert Lisicki
CEO | Chief Executive Officer | 57 | Jan. 07 |
Verender Badial
DFI | Director of Finance/CFO | 51 | 23-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Amit Munshi
CHM | Chairman | 56 | 23-02-28 |
Steven Schoch
BRD | Director/Board Member | 64 | 23-02-28 |
Sandeep Kulkarni
BRD | Director/Board Member | 43 | 22-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.53% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 4.64 | -1.07% | 72 888 |
| 24-05-06 | 4.69 | +1.52% | 137,068 |
| 24-05-03 | 4.62 | +5.96% | 296,843 |
| 24-05-02 | 4.36 | +5.06% | 121,769 |
| 24-05-01 | 4.15 | -2.81% | 248,775 |
End-of-day quote Nasdaq, May 06, 2024
More quotes
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.64
USD
Average target price
18
USD
Spread / Average Target
+287.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.64% | 289M | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +7.89% | 23.47B | |
| -13.89% | 21.9B | |
| -6.36% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +8.67% | 14.41B | |
| +41.08% | 12.86B |
- Stock Market
- Equities
- ZURA Stock